LENSAR, Inc.
Close on Oct 19, 2026
- Market cap
- $132.41M
- P/E (TTM)
- –
- Dividend yield
- –
About Lensar
Surgical & Medical Instruments & Apparatus, SIC 3841
LENSAR, Inc. is a commercial-stage medical device company that develops, designs, and markets advanced femtosecond laser systems. Its primary offerings include the LENSAR Laser System and the next-generation ALLY Robotic Cataract Laser System, which integrate proprietary technologies such as advanced imaging and procedural planning to support ophthalmic procedures. The company’s systems are designed for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its customer base consists of ophthalmic cataract surgeons, practices, and ambulatory surgery centers.
The company operates its principal executive offices in Orlando, Florida. Its product offerings are commercially available across the United States and the European Union, with additional regulatory clearances obtained in international markets including India and Taiwan. Distribution and commercialization efforts occur domestically through direct sales initiatives as well as internationally through global distributor networks.
Summary of the business section of Lensar's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LENSAR, Inc.
- Headquarters
- Orlando, FL
- Address
- 2800 Discovery Drive, Suite 100 32826
- Phone
- (888) 536-7271
- Employees
- 150, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- LNSR
- Exchange
- Nasdaq
- IPO date
- Oct 2, 2020
- Shares outstanding
- 12M, Jul 31, 2026
- Public float
- $113.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1320350
- CUSIP
- 52634L108
- ISIN
- US52634L1089
- EIN
- 32-0125724
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nicholas T. Curtis | Chief Executive Officer, Director | 1,122,758 |
| Michael A. Rossi | Interim CFO | – |
| Alan B. Connaughton | Chief Operating Officer | 389,173 |
| Kendra Wong | Principal Accounting Officer | 56,481 |
| Thomas R. Staab Ii | Chief Financial Officer | 174,609 |
| Elizabeth G. O'Farrell | Director | 67,368 |
| Gary M. Winer | Director | 105,635 |
| Richard L. Lindstrom Md | Director | 263,831 |
| Todd B. Hammer | Director | 1,156,675 |
| William J. Link Phd | Director | 568,062 |
| Aimee S. Weisner | Director | 110,368 |
| Thomas B. Ellis | Director | 1,156,675 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Curtis | $2.34M | $3.19M | $928.74K | $331 | – |
| FY2024 Mr. Curtis | $1.58M | $3.00M | $916.44K | $255 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 150 employees that support our manufacturing, research and development, commercial and administrative functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 19, 2025 | Merger vote | Definitive merger proxy statement |
| Aug 26, 2020 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
| Jun 16, 2006 | Name change | Name changed from LaserSoft Vision Inc to LensAR Inc |